This Article Full Text Full Text (PDF) All Versions of this Article: 27/1/15    most recent 01.ATV.0000251503.35795.4fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koenig, W. Articles by Khuseyinova, N. Search for Related Content PubMed PubMed Citation Articles by Koenig, W. Articles by Khuseyinova, N.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:15.)
© 2007 American Heart Association, Inc.

Brief Reviews

Biomarkers of Atherosclerotic Plaque Instability and Rupture

Wolfgang Koenig; Natalie Khuseyinova

From the Department of Internal Medicine II–Cardiology, University of Ulm Medical Center, Germany.

Correspondence to Wolfgang Koenig, MD, FRCP, FESC, FACC, Department of Internal Medicine II–Cardiology, University of Ulm Medical Center, Robert-Koch Str. 8, D-89081 Ulm, Germany. E-mail wolfgang.koenig{at}uniklinik-ulm.de

Editor: Willliam Haynes
Noninvasive Assessment of Atherosclerosis: From Structure to Function
ATVB In Focus

Previous Brief Reviews in this Series:

•Choudhury RP, Fuster V, Badimon JJ. Fisher EA, Fayad ZA. MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. 2002;22:1065–1074.
•Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. 2003;23:168–175.
•Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. 2003;23:554–566.
•Madjid M, Zarrabi A, Litovsky S, Willerson JT, Casscells W. Finding vulnerable atherosclerotic plaques: is it worth the effort? 2004;24:1775–1782.
•Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. 2005;25:279–286.
•Feinbloom D, Bauer KA. Assessment of hemostatis risk factors in predicting arterial thrombotic events. 2005;25:2043–2053.
•Oliver JJ, Webb DJ, Newby, DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. 2005:25:2470–2479.

Basic research over the last two decades has identified a large number of molecules pertinent to the atherosclerotic process, which have clearly improved our understanding of the underlying pathology. It is now well established that inflammation represents a major feature which is present in the vessel wall throughout all stages of the disease until the final pathophysiologic steps, representing plaque destabilization and eventually plaque rupture. Several cells typical for the atherosclerotic plaque, like monocyte-derived macrophages and T-lymphocytes are able to produce and secrete such mediator molecules, like cytokines, chemokines, growth-factors, enzymes, and disintegrins, which lead to activation of endothelial cells, proliferation of smooth muscle cells, lesion progression, and finally to the weakening of a vulnerable plaque by matrix degradation of its fibrous cap. Today, many of these molecules involved can be measured systemically by sensitive assays, and elevated concentrations in the circulation have been shown to be associated with future cardiovascular events. Determination of several of these molecules carries important prognostic information, independent of traditional risk factors, and may turn out to be useful in improving risk stratification. However, for most of these biomarkers the clinical utility has not yet been established.

Basic research over the last two decades has identified a large number of biomarkers of atherosclerotic plaque destabilization and rupture, which carry important prognostic information and might be useful in improving risk stratification in the future. To date, however, none of them can be recommended for routine clinical use.

Key Words: biomarkers • atherosclerosis • pathophysiology • risk prediction

This article has been cited by other articles:

				L. Zhao, E. Lee, A. M. Zukas, M. K. Middleton, M. Kinder, P. S. Acharya, J. A. Hall, D. J. Rader, and E. Pure CD44 Expressed on Both Bone Marrow-Derived and Non-Bone Marrow-Derived Cells Promotes Atherogenesis in ApoE-Deficient Mice Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1283 - 1289. [Abstract] [Full Text] [PDF]

				V. Croons, W. Martinet, A. G. Herman, and G. R. Y. De Meyer Differential Effect of the Protein Synthesis Inhibitors Puromycin and Cycloheximide on Vascular Smooth Muscle Cell Viability J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 824 - 832. [Abstract] [Full Text] [PDF]

				E. Debing, E. Peeters, C. Demanet, M. De Waele, and P. Van den Brande Markers of Inflammation in Patients With Symptomatic and Asymptomatic Carotid Artery Stenosis: A Case-Control Study Vascular and Endovascular Surgery, May 1, 2008; 42(2): 122 - 127. [Abstract] [PDF]

				A. Malarstig, S. Sigurdsson, P. Eriksson, G. Paulsson-Berne, U. Hedin, L. Wallentin, A. Siegbahn, A. Hamsten, and A.-C. Syvanen Variants of the Interferon Regulatory Factor 5 Gene Regulate Expression of IRF5 mRNA in Atherosclerotic Tissue But Are Not Associated With Myocardial Infarction Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 975 - 982. [Abstract] [Full Text] [PDF]

				E. R. Mohler III, C. M. Ballantyne, M. H. Davidson, M. Hanefeld, L. M. Ruilope, J. L. Johnson, A. Zalewski, and for the Darapladib Investigators The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1632 - 1641. [Abstract] [Full Text] [PDF]

				R. J. Petrovan, Y. Yuan, and L. K. Curtiss Expression of the Lystbeige mutation is atheroprotective in chow-fed apolipoprotein E-deficient mice J. Lipid Res., February 1, 2008; 49(2): 429 - 437. [Abstract] [Full Text] [PDF]

				J. G. Schneider, Y. Zhu, T. Coleman, and C. F. Semenkovich Macrophage 3 Integrin Suppresses Hyperlipidemia-Induced Inflammation by Modulating TNF{alpha} Expression Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2699 - 2706. [Abstract] [Full Text] [PDF]

				R. C. Becker Emerging Paradigms, Platforms, and Unifying Themes in Biomarker Science J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1777 - 1780. [Full Text] [PDF]

				P. K. Cheruvu, A. V. Finn, C. Gardner, J. Caplan, J. Goldstein, G. W. Stone, R. Virmani, and J. E. Muller Frequency and Distribution of Thin-Cap Fibroatheroma and Ruptured Plaques in Human Coronary Arteries: A Pathologic Study J. Am. Coll. Cardiol., September 4, 2007; 50(10): 940 - 949. [Abstract] [Full Text] [PDF]

				W. Koenig Cardiovascular Biomarkers: Added Value With an Integrated Approach? Circulation, July 3, 2007; 116(1): 3 - 5. [Full Text] [PDF]

				W. Koenig Serum Amyloid P Component and Cardiovascular Disease: Is There a Sensible Link? Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 698 - 700. [Full Text] [PDF]